Amgen Inc.

Japan Tobacco Inc.

Yasuhiro Ohe

Jay Patrick Powers

Shinji Yata

Makoto Kakutani

Hiroyuki Goto

Mario G Cardozo

Kazuhito Harada

Katsuaki Imamura

Isamu Matsuda

Taku Ikenogami

Atsushi Hagiwara

Toshio Taniguchi

Hua Tu

Jun Nishiu

Naoya Odani

Shizue Watanabe

Takashi Kawai

Kenya Madono

The present invention provides a triazole compound of the following formula: a prodrug thereof or a pharmaceutically acceptable salt thereof. The above-mentioned triazole compound has superior HSD1 inhibitory activity, and is useful as an HSD1 inhibitor, a therapeutic drug of diabetes or a therapeutic drug of obesity or a therapeutic drug of metabolic syndrome.

Triazole compounds and uses related thereto

The present invention provides a triazole compound of the following formula: a prodrug thereof or a pharmaceutically acceptable salt thereof. The above-mentioned triazole compound is useful as a therapeutic drug for the treatment of diabetes, obesity or metabolic syndrome. 

A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1&#x2033;) (wherein The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.

Ester compound and medicinal use thereof

Substituted pyrazoles are provided that are useful for the treatment of, for example, diabetes, obesity and metabolic syndrome.

Pyrazole compounds and uses related thereto

Growing community of inventors

Takatsuki, Japan

Yasuhiro Ohe